Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Buspirone Hydrochloride
Therapeutic Area : Psychiatry/Psychology
Study Phase : IND Enabling
Recipient : Cingulate Therapeutics
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : CTx-2103 (Buspirone Hydrochloride) is a novel, trimodal, extended-release tablet of buspirone incorporating Cingulate’s proprietary PTR™ drug delivery platform, and is being studied for the treatment of anxiety and/or anxiety-related disorders.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 24, 2022
Lead Product(s) : Buspirone Hydrochloride
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : IND Enabling
Recipient : Cingulate Therapeutics
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : ALLN-346
Therapeutic Area : Rheumatology
Study Phase : Phase I
Recipient : Allena Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
Scintigraphy Study in Healthy Volunteers to Characterize the Performance of ALLN-346 Tablets
Details : Undisclosed
Product Name : Undisclosed
Product Type : Enzyme
Upfront Cash : Inapplicable
December 23, 2021
Lead Product(s) : ALLN-346
Therapeutic Area : Rheumatology
Highest Development Status : Phase I
Recipient : Allena Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Sildenafil Citrate
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase I
Recipient : N4 Pharma
Deal Size : Inapplicable
Deal Type : Inapplicable
Pharmacoscintigraphic Study to Evaluate Two Sildenafil Products
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 27, 2018
Lead Product(s) : Sildenafil Citrate
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase I
Recipient : N4 Pharma
Deal Size : Inapplicable
Deal Type : Inapplicable
Delayed Release Diclofenac Sodium Formulation vs Voltaren®
Details : Undisclosed
Product Name : Undisclosed
Product Type : Radiolabeled Compounds
Upfront Cash : Inapplicable
March 22, 2016
A Study to Investigate Delayed-release Tablets
Details : Undisclosed
Product Name : Undisclosed
Product Type : Radiolabeled Compounds
Upfront Cash : Inapplicable
December 09, 2013
Lead Product(s) : OligoG CF-5/20
Therapeutic Area : Genetic Disease
Study Phase : Phase II
Sponsor : AlgiPharma
Deal Size : Inapplicable
Deal Type : Inapplicable
A Study to Investigate Lung Deposition of Radiolabelled OligoG
Details : Undisclosed
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
November 25, 2013
Lead Product(s) : OligoG CF-5/20
Therapeutic Area : Genetic Disease
Highest Development Status : Phase II
Sponsor : AlgiPharma
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
